| Name | GS-441524 |
| Description | GS-441524 treatment of cats with naturally occurring feline infectious peritonitis. |
| Animal Research | Cats ranged from 3.4-73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five had non-effusive disease. Cats with severe neurological and ocular FIP were not recruited. The group was started on GS-441524 at a dosage of 2.0 mg/kg SC q24h for at least 12 weeks and increased when indicated to 4.0 mg/kg SC q24h[1]. |
| In vivo | Four of the 31 cats that presented with severe disease died or were euthanized within 2-5 days and a fifth cat after 26 days. The 26 remaining cats completed the planned 12 weeks or more of treatment(GS-441524). Eighteen of these 26 cats remain healthy at the time of publication after one round of treatment, while eight others suffered disease relapses within 3-84 days. Six of the relapses were non-neurological and two neurological. Three of the eight relapsing cats were treated again at the same dosage, while five cats had the dosage increased from 2.0 to 4.0 mg/kg q24h. The five cats treated a second time at the higher dosage, including one with neurological disease, responded well and also remain healthy . However, one of the three cats re-treated at the original lower dosage relapsed with neurological disease and was euthanized, while the two remaining cats responded favorably but relapsed a second time. These two cats were successfully treated a third time at the higher dosage, producing 25 long-time survivors. One of the 25 successfully treated cats was subsequently euthanized due to presumably unrelated heart disease, while 24 remain healthy[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.87 mM), Sonication is recommended.
DMSO : 247.5 mg/mL (849.76 mM), Sonication is recommended.
|
| Keywords | virus | SARS-CoV | SARSCoV | SARS coronavirus | RNASynthesis | RNA Synthesis | peritonitis | GS-441524 Triphosphate | GS441524 Triphosphate | GS-441524 | GS441524 | GS 441524 | FIPV | feline | DNASynthesis | DNA/RNA Synthesis | DNA Synthesis |
| Inhibitors Related | 5-Fluorouracil | Adenine hemisulfate | Erythromycin thiocyanate | Guanidine hydrochloride | Hydroxychloroquine | Hexane-1,6-diol | 1,4-Naphthoquinone | Adenine | Vidarabine | Carbazole | Thymidine | Usnic Acid |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Orally Active Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Cell Cycle Compound Library | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library |
United States
